dorgenmeltucel-L + pembrolizumab

dorgenmeltucel-L + pembrolizumab is a combination therapy composed of a cancer vaccine (dorgenmeltucel-L) and an immune checkpoint inhibitor (pembrolizumab). - Dorgenmeltucel-L is a dendritic cell-based cancer vaccine designed to stimulate the patient’s immune system to recognize and attack tumor cells by presenting tumor-associated antigens. - Pembrolizumab is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1) on T cells, blocking the interaction with its ligands PD-L1 and PD-L2, thereby enhancing the anti-tumor immune response. - Pembrolizumab is approved and widely used for the treatment of multiple cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and many others[2][5][8]. - The combination seeks to augment anti-tumor immunity by both active vaccination (dorgenmeltucel-L) and checkpoint blockade (pembrolizumab). - Developer(s): Dorgenmeltucel-L development has been led by GlobeImmune; pembrolizumab was developed by Organon (now part of Merck)[5].